EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection

Anna Maria Geretti, Alexandre Sostelly, Simon Buatois, Sijie Lu, Annabelle Lemenuel, Gemma Attley iD, Martin Bopst, Rubén Alvarez-Sánchez, Henrik Mueller, Edward Gane

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00679-25 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Anna Maria Geretti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Oligonucleotides, Antisense, Oligonucleotides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly(A) RNA polymerases D5 and D7 (PAPD5, PAPD7) are host factors that stabilize hepatitis B virus (HBV) RNA transcripts. RO7239958, a liver-targeted locked nucleic acid (LNA) antisense oligonucleotide (ASO), induces intracellular degradation of PAPD5- and PAPD7-encoding messenger RNAs (mRNAs). This first-in-human study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7239958 in healthy volunteers and adults with chronic hepatitis B (CHB) receiving standard-of-care antiviral therapy. Forty healthy volunteers were randomized (4:1) to single ascending subcutaneous doses of RO7239958 (0.1, 0.3, 1.0, or 1.5 mg/kg) or placebo. Based on a population PK model built to predict liver exposure, two parallel CHB cohorts ( n = 8 and n = 7 per cohort) were randomized to two 4-weekly doses of RO7239958 (0.2 or 0.4 mg/kg) or placebo. RO7239958 plasma exposure increased more than dose-proportionally at dose levels of 1.0 and 1.5 mg/kg, suggesting saturation of liver uptake. RO7239958 was generally well tolerated in healthy volunteers; transaminase elevations occurred at the highest doses, including one reversible Grade 3 elevation. The PK model indicated that doses of 0.2 and 0.4 mg/kg would reduce PAPD5 and PAPD7 mRNA by 50% and 62%, respectively, with minimal liver toxicity. Consistent with predictions, RO7239958 was well-tolerated and safe in patients. At 0.4 mg/kg, the maximum reduction from baseline in serum hepatitis B surface antigen was observed on Day 43 (mean decline 0.2 log 10 IU/mL; range 0.0–0.5 log 10 IU/mL). While RO7239958 showed a potentially narrow therapeutic window, PAPD5 and PAPD7 remain potential therapeutic targets in HBV curative strategies. CLINICAL TRIALS This study was registered at NCT03762681 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicAntiviral AgentsOligonucleotides, AntisenseOligonucleotidesHumansAdultMaleFemaleHealthy VolunteersMiddle AgedHepatitis B virusYoung AdultDouble-Blind MethodLiver

Stichwörter der Autor:innen

PAPD5PAPD7RO7239958TENT4ATENT4Bcurehepatitis B viruslocked-nucleic acidpharmacodynamicspharmacokineticssingle-stranded oligonucleotide

Substanzen

Antiviral AgentsOligonucleotides, AntisenseOligonucleotides

Autor:innen und Institutionen

  • Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
  • Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
  • Roche Pharma Research and Early Development, Roche Innovation Center New York, , Little Falls, New Jersey, USA.
  • Auckland Clinical Studies, Auckland, New Zealand.

ORCID-Profile: Gemma Attley

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Geretti, A. M., Sostelly, A., Buatois, S., Lu, S., Lemenuel, A., Attley, G., Bopst, M., Alvarez-Sánchez, R., Mueller, H., & Gane, E. (2025). Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00679-25

Vancouver

Geretti AM, Sostelly A, Buatois S, Lu S, Lemenuel A, Attley G, et al. Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00679-25

BibTeX
@article{Geretti2025,
  author = {Geretti, Anna Maria and Sostelly, Alexandre and Buatois, Simon and Lu, Sijie and Lemenuel, Annabelle and Attley, Gemma and Bopst, Martin and Alvarez-Sánchez, Rubén and Mueller, Henrik and Gane, Edward},
  title = {Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00679-25}
}
Kostenlos starten →